Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we rep...
Source: Allergy, Asthma and Clinical Immunology - Category: Allergy & Immunology Authors: Qingqing Yang, Jiajie Lyu, Yu Gui, Shuling Yu, Jiajie Chen, Haoxue Zhang and Shengxiu Liu Tags: Case report Source Type: research
More News: Allergy | Allergy & Immunology | Arthritis | Asthma | European Medicines Agency (EMA) | Psoriasis | Psoriatic Arthritis | Rheumatology